A PHASE II MULTICENTER TRIAL OF INTRATUMORAL/INTERSTITIAL THERAPY WITH HN-6600

HN-66000是一种突变白喉的专利药物配方 毒素和人类转铁蛋白被开发为一种潜在的治疗- 恶性脑瘤的药物治疗。由I期试验赞助的结果 美国国立卫生研究院的研究表明，该药物在患有癌症的患者中产生肿瘤反应 非重症常规治疗难于治疗的恶性脑瘤 神经系统或全身毒性。装饰的结果证明了 第二阶段试验中的扩展评估。

HN-66000 is a proprietary pharmaceutical formulation of mutant diphthieria toxin and human transferrin that is beng developed as a potential treat- ment for malignant brain tumors.The results from Phase I trial sponsored by the NIH suggest that the drug produces tumor responses in patients with malignant brain tumors refractory to conventional therapy without severe neurologic or systemic toxcicity. The encoraging results warrant an expanded evaluation in a phase II trail.